RxDoctor Payments Data

Lokesh Edara, MD

Allergy · Battle Creek, MINPI 1104890490

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.5% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.

$2,567in general payments, 2019–2025

Across 147 payments — averaging $17.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$462
  • GSK$320
  • Novartis$272
  • Regeneron Healthcare Solutions, Inc.$267
  • AstraZeneca$244
  • Teva Pharmaceuticals USA, Inc.$211
  • plus $791 from 16 others

What the payments were for

  • Food & beverage$2,55399%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,567 in reported general payments places this provider in the 55th percentile of 22 allergy providers in Michigan.

See all allergy providers in Michigan

Medicare billing

Part B allowed, 2024
$41,869
Medicare patients
126
Services billed
3,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab14$44,565
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$14,123
Fluticasone-SalmeterolFluticasone Propion/Salmeterol59$12,191
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate35$9,739
Breo ElliptaFluticasone/Vilanterol21$9,662
Advair HfaFluticasone Propion/Salmeterol19$7,284
Epinephrine16$3,779
Azelastine Hcl64$2,497
Ipratropium Bromide57$2,201
Albuterol Sulfate HfaAlbuterol Sulfate59$2,194
Fluticasone Propionate61$1,436
Montelukast Sodium117$1,206
Levocetirizine Dihydrochloride45$578
Azithromycin13$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$320$23,78535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 22 allergy providers in Michigan.

Other allergy in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →